Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 57Recruiting 48Completed 45Terminated 15Not yet recruiting 15Active not recruiting 12Withdrawn 3Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Cancer Non-resectable 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 9Standard of Care 6Educational Status 6Nivolumab 5Interviews as Topic 5Carboplatin 5Radiotherapy 4Paclitaxel 4Oxaliplatin 4Dexamethasone 4pembrolizumab 3camrelizumab 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Fluorouracil 3Fluorodeoxyglucose F18 3Exercise 3Early Intervention, Educational 3Drug Therapy 3Cytarabine 3130-nm albumin-bound paclitaxel 3venetoclax 2toripalimab 2tislelizumab 2sacituzumab govitecan 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Chemoradiotherapy × Clear all
NCT07386704 2026-02-04

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Peking University First Hospital

Phase 2 Enrolling by invitation
30 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT06048926 2023-09-21

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase NA Enrolling by invitation
30 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡